ATE358716T1 - Polypeptide zur auslösung einer immunreaktion gegen krebs - Google Patents

Polypeptide zur auslösung einer immunreaktion gegen krebs

Info

Publication number
ATE358716T1
ATE358716T1 AT01272392T AT01272392T ATE358716T1 AT E358716 T1 ATE358716 T1 AT E358716T1 AT 01272392 T AT01272392 T AT 01272392T AT 01272392 T AT01272392 T AT 01272392T AT E358716 T1 ATE358716 T1 AT E358716T1
Authority
AT
Austria
Prior art keywords
polypeptides
against cancer
triggering
immune response
response against
Prior art date
Application number
AT01272392T
Other languages
English (en)
Inventor
Gustav Gaudernack
Stein Saeboe-Larssen
Mona Moller
Jon Amund Eriksen
Original Assignee
Gemvax As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9905720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE358716(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gemvax As filed Critical Gemvax As
Application granted granted Critical
Publication of ATE358716T1 publication Critical patent/ATE358716T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT01272392T 2000-12-22 2001-12-18 Polypeptide zur auslösung einer immunreaktion gegen krebs ATE358716T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0031430.2A GB0031430D0 (en) 2000-12-22 2000-12-22 Polypeptides

Publications (1)

Publication Number Publication Date
ATE358716T1 true ATE358716T1 (de) 2007-04-15

Family

ID=9905720

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01272392T ATE358716T1 (de) 2000-12-22 2001-12-18 Polypeptide zur auslösung einer immunreaktion gegen krebs
AT07105178T ATE550426T1 (de) 2000-12-22 2001-12-18 Polypeptide zur auslösung einer immunreaktion gegen krebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07105178T ATE550426T1 (de) 2000-12-22 2001-12-18 Polypeptide zur auslösung einer immunreaktion gegen krebs

Country Status (14)

Country Link
US (4) US7078416B2 (de)
EP (3) EP2361978B1 (de)
JP (3) JP2004522433A (de)
AT (2) ATE358716T1 (de)
AU (3) AU2002216477B2 (de)
CA (2) CA2432971C (de)
CY (2) CY1106564T1 (de)
DE (1) DE60127715T2 (de)
DK (3) DK2361978T3 (de)
ES (2) ES2382821T3 (de)
GB (1) GB0031430D0 (de)
NO (2) NO332137B1 (de)
PT (2) PT1862544E (de)
WO (1) WO2002051994A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
AU2001241533A1 (en) * 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
WO2004058157A2 (en) * 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1601684B1 (de) * 2003-03-05 2014-10-15 Dendreon Corporation Zusammensetzungen und verfahren unter anwendung von polypeptiden mit alternativem leserahmen zur behandlung von krebs und infektionskrankheiten
AU2005295317B2 (en) 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
US11771749B2 (en) 2017-02-03 2023-10-03 The Medical College Of Wisconsin, Inc. KRAS peptide vaccine compositions and method of use
WO2018223094A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized canine cancer vaccines
US20200209241A1 (en) 2017-09-15 2020-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
EP4038222A4 (de) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Verfahren und zusammensetzungen zur identifizierung von neoantigenen zur verwendung bei der behandlung und vorbeugung von krebs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
CA2294782A1 (en) * 1997-07-01 1999-01-14 Cambia Biosystems Llc Vertebrate telomerase genes and proteins and uses thereof
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
US6362784B1 (en) * 1998-03-31 2002-03-26 Matsuda Electric Industrial Co., Ltd. Antenna unit and digital television receiver
JP2002509716A (ja) * 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
CA2368967A1 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine
WO2000073801A2 (en) 1999-05-28 2000-12-07 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides

Also Published As

Publication number Publication date
US20120269858A1 (en) 2012-10-25
AU2010200620B2 (en) 2012-11-01
JP2012080883A (ja) 2012-04-26
WO2002051994A8 (en) 2003-03-06
WO2002051994A3 (en) 2002-12-27
JP2014138587A (ja) 2014-07-31
CA2782510A1 (en) 2002-07-04
WO2002051994A2 (en) 2002-07-04
US7375117B2 (en) 2008-05-20
ES2382821T3 (es) 2012-06-13
EP2361978A1 (de) 2011-08-31
US20080187551A1 (en) 2008-08-07
NO20032818L (no) 2003-08-21
AU2007211889C1 (en) 2010-06-10
AU2010200620A1 (en) 2010-03-11
US7078416B2 (en) 2006-07-18
CA2432971C (en) 2012-09-04
PT1352056E (pt) 2007-05-31
ES2280311T3 (es) 2007-09-16
AU2007211889A1 (en) 2007-09-13
JP2004522433A (ja) 2004-07-29
AU2002216477B2 (en) 2007-05-24
DK1352056T3 (da) 2007-05-29
EP1352056B1 (de) 2007-04-04
DE60127715T2 (de) 2007-12-27
EP1862544A1 (de) 2007-12-05
AU2007211889B8 (en) 2009-12-10
AU2007211889B2 (en) 2009-11-19
CY1112735T1 (el) 2016-02-10
EP1352056A2 (de) 2003-10-15
EP1862544B2 (de) 2016-03-09
AU2002216477C1 (en) 2002-07-08
US20040072759A1 (en) 2004-04-15
NO20110429L (no) 2003-08-21
NO342257B1 (no) 2018-04-30
EP2361978B1 (de) 2015-10-14
DK2361978T3 (en) 2016-01-25
ATE550426T1 (de) 2012-04-15
GB0031430D0 (en) 2001-02-07
EP1862544B1 (de) 2012-03-21
DE60127715D1 (de) 2007-05-16
NO20032818D0 (no) 2003-06-19
CY1106564T1 (el) 2012-01-25
CA2782510C (en) 2014-07-15
CA2432971A1 (en) 2002-07-04
DK1862544T3 (da) 2012-07-09
US8193326B2 (en) 2012-06-05
PT1862544E (pt) 2012-05-07
NO332137B1 (no) 2012-07-02
US20060194731A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
NO20110429L (no) Polypeptider og nukleinsyre-DNA for anvendelse innen medisin
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1106806T1 (el) Dna και πολυπεπτιδια ανθρωπινης tslp
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
ATE315088T1 (de) Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
WO2002080851A3 (en) Chimeric vaccines
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
ATE386106T1 (de) Rekombinante poxvirus-cytomegalovirus zusammensetzungen und ihre verwendung
EP1289551A4 (de) HUMANE POLYPEPTIDE WELCHE ZUM ABSTERBEN VON ZELLEN, INSBESONDERE LYMPHOIDER TUMORZELLEN, FüHREN
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
WO1997048370A3 (en) Vaccines comprising synthetic genes
AU5810201A (en) Immunogenic polypeptides encoded by mage minigenes and uses thereof
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
BR9711795A (pt) Peptìdeos tendo propriedades antiproliferativas
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
WO2005007673A3 (en) Immunogenic peptides
DK1536006T3 (da) Cancerantigener og anvendelse deraf
WO2001074845A3 (en) Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
WO2003093298A3 (en) Immunogenic peptides
DE69934953D1 (de) Impstoffe gegen Coccidiosis
AU1572702A (en) Novel immunomodulatory protein and useful embodiments thereof
WO2002002771A3 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1352056

Country of ref document: EP